OvaTrack
A recurrence-aware companion app for ovarian cancer patients that logs symptoms and CA-125 trends over years and surfaces treatment and clinical-trial options specific to recurrence.
women living with ovarian cancer, especially those in or worried about recurrence
- Symptom and CA-125 log that plots trends over months and flags values that drift from the survivor's own baseline
- Treatment timeline that shows each chemo regimen, response, and side-effect pattern side by side
- Curated clinical-trial feed filtered by recurrence status, stage, and known mutations
- Private moderated cohort chat limited to verified ovarian-cancer patients
Evert's third recurrence during Wimbledon coverage put a rare public spotlight on ovarian cancer recurrence and the lack of recurrence-specific patient tools; ~20,000 US women are diagnosed each year and recurrence rates remain high.
Real but narrow pool: ~20K US ovarian cancer diagnoses/yr with high recurrence, and existing generic cancer trackers (Wave Health, Outcomes4Me) already attract users tracking CA-125; ovarian-recurrence-specific symptom-logging demand is unproven at scale.Wave Health Symptom Tracker | Get insights about your health ↗Ovarian Cancer Recurrence Symptoms and Detection Guide ↗
No app found that is specifically ovarian-cancer-recurrence-focused combining CA-125 trend analysis with recurrence-specific clinical-trial matching, but Outcomes4Me (free, NCCN-backed, already does trial matching across cancers) sits adjacent and could trivially add an ovarian module.Outcomes4Me: Cancer Care Guidance for Patients ↗204+ Best Cancer Tracker Apps for iPhone (2026) | Free & Paid ↗
Direct-to-patient pricing is weak: Outcomes4Me and Wave Health are free, and 204+ cancer tracker apps skew free/freemium; ovarian cancer patients often face high financial toxicity, so willingness to pay is low without a pharma B2B or payer channel, which is unproven for this niche.Outcomes4Me Reviews and Pricing 2026 | F6S ↗204+ Best Cancer Tracker Apps for iPhone (2026) | Free & Paid ↗
Recurrence surveillance for ovarian cancer typically spans years (recurrence rates 70%+ for advanced disease), so logged longitudinal CA-125/symptom data is sticky, but patient retention drops if no clinical action is surfaced.Rising serum CA-125 levels within the normal range is strongly ... ↗Remission & recurrence - Ovarian Cancer Canada ↗
CA-125 logging and symptom diary are trivially buildable, but recurrence-aware clinical-trial matching requires a curated trial database plus matching logic (Outcomes4Me already does this at scale), and any diagnostic-adjacent claim triggers HIPAA/FDA SaMD review and clinical-validation burden.Outcomes4Me: Cancer Care Guidance for Patients ↗Ovarian Cancer Market: Epidemiology, Treatments, and Key Players ↗